PubRank

Ziad Massy

Author PubWeight™ 46.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 2007 2.99
2 Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008 2.96
3 Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010 1.90
4 Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004 1.81
5 Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010 1.59
6 Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002 1.58
7 CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008 1.57
8 Diagnosis of central hypovolemia by using passive leg raising. Intensive Care Med 2007 1.39
9 Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. Nat Clin Pract Nephrol 2006 1.39
10 Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. J Hypertens 2010 1.21
11 Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol 2011 1.20
12 Pulmonary hypertension in CKD. Am J Kidney Dis 2012 1.19
13 Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant 2011 1.12
14 Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol 2011 1.10
15 p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 2013 1.04
16 Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis 2005 0.99
17 Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation. Blood Purif 2010 0.92
18 Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007 0.92
19 Oxidized low density lipoprotein inhibits phosphate signaling and phosphate-induced mineralization in osteoblasts. Involvement of oxidative stress. Biochim Biophys Acta 2010 0.91
20 Review on uraemic solutes II--variability in reported concentrations: causes and consequences. Nephrol Dial Transplant 2007 0.89
21 an Obituary for GFR as the main marker for kidney function? Semin Dial 2011 0.87
22 Oxidized low-density lipoprotein elicits an intracellular calcium rise and increases the binding activity of the transcription factor NFAT. Free Radic Biol Med 2005 0.86
23 Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction. Am J Cardiol 2008 0.86
24 Inconsistency of reported uremic toxin concentrations. Artif Organs 2007 0.86
25 Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005 0.84
26 Implication of the calcium sensing receptor and the Phosphoinositide 3-kinase/Akt pathway in the extracellular calcium-mediated migration of RAW 264.7 osteoclast precursor cells. Bone 2010 0.81
27 Total calcium-sensing receptor expression in circulating monocytes is increased in rheumatoid arthritis patients with severe coronary artery calcification. Arthritis Res Ther 2014 0.81
28 Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. J Cell Physiol 2009 0.80
29 Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease. Nephron Clin Pract 2010 0.79
30 [Recommended dosage adaptation based on renal function is not always sufficient to avoid betalactam antibiotics side effects]. Nephrol Ther 2008 0.79
31 Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit. Semin Dial 2009 0.79
32 The use of echocardiography in observational clinical trials: the EURECA-m registry. Nephrol Dial Transplant 2012 0.78
33 Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial 2009 0.78
34 Beyond phosphate--role of uraemic toxins in cardiovascular calcification. Nephrol Dial Transplant 2006 0.77
35 High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. Atherosclerosis 2010 0.77
36 Clinical features and prognosis of heart failure in women. A 5-year prospective study. Int J Cardiol 2008 0.77
37 Determination and modulation of total and surface calcium-sensing receptor expression in monocytes in vivo and in vitro. PLoS One 2013 0.77
38 Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol 2008 0.77
39 Uremia-related oxidative stress in leukocytes is not triggered by β2-microglobulin. J Ren Nutr 2013 0.76
40 Cinacalcet and vascular calcifications induced by calcitriol. Nephrol Dial Transplant 2005 0.75
41 [Oxidative stress in end stage renal disease: evidence and association with cardiovascular events in Tunisian patients]. Tunis Med 2006 0.75
42 Overview of randomised trials of ACE inhibitors. Lancet 2006 0.75
43 Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2004 0.75
44 Risk factors of the progression of abdominal aortic calcification in patients on chronic haemodialysis. Nephrol Dial Transplant 2007 0.75
45 Drug Insight: renal indications of calcimimetics. Nat Clin Pract Nephrol 2006 0.75
46 [French-Brazilian school of nephrology]. Nephrol Ther 2012 0.75
47 [Renal and urinary tract disease national research program]. Nephrol Ther 2007 0.75